Bristol-Myers Squibb Co
Change company Symbol lookup
Select an option...
BMY Bristol-Myers Squibb Co
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
BGSF BGSF Inc
NEE Nextera Energy Inc
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Premarket

Last Trade
Delayed
$55.58
0.17 (0.31%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$55.41
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
776

10-day average volume:
16,638,391
776

Company Profile

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
2.68x
Price/Book (MRQ)
3.28x
Price/Cash Flow (TTM)
22.35x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

November 2021
Current Month
20.3M
Previous Month
22.4M
Percent of Float
0.91%
Days to Cover
1.8909 Days

Share Information

BMY is in a share class of common stock
Float
2.2B
Shares Outstanding
2.2B
Institutions Holding Shares
2,894
72.92%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Giovanni CaforioChmn.
  • David V. ElkinsCFO
  • Ann M. Powell
  • Sandra LeungExec.VP
  • Christopher S. BoernerExec.VP

Address

  • 430 E 29Th St Fl 14
  • New York, NY 10016-8367
  • Phone: (212) 546-4000
  • Fax: (302) 655-5049
  • https://www.bms.com/

Insider Trading

During the most recent quarter, 434K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.